Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.350
-0.005 (-1.44%)
At close: Nov 20, 2024, 4:00 PM
0.347
-0.003 (-0.83%)
Pre-market: Nov 21, 2024, 5:46 AM EST
Enveric Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 5.16 | 8.97 | 11.73 | 19.88 | 5.32 | 2.3 | |
| Research & Development | 3.34 | 7.14 | 7.91 | 4.76 | 0.17 | - | |
| Operating Expenses | 8.84 | 16.45 | 19.96 | 25.29 | 5.62 | 2.3 | |
| Operating Income | -8.84 | -16.45 | -19.96 | -25.29 | -5.62 | -2.3 | |
| Interest Expense | -0 | - | -0.01 | -0.01 | -0.45 | -0.08 | |
| Interest & Investment Income | 0 | 0 | - | - | - | - | |
| Other Non Operating Income (Expenses) | -0.99 | -0.82 | 7.46 | 8.2 | -0.8 | - | |
| EBT Excluding Unusual Items | -9.83 | -17.26 | -12.5 | -17.1 | -6.86 | -2.38 | |
| Merger & Restructuring Charges | - | - | - | -0.65 | - | - | |
| Impairment of Goodwill | - | - | -1.49 | -8.23 | - | - | |
| Asset Writedown | - | - | -5.97 | -30.45 | - | - | |
| Other Unusual Items | - | - | - | - | - | -0.03 | |
| Pretax Income | -9.83 | -17.26 | -19.96 | -56.43 | -6.86 | -2.41 | |
| Income Tax Expense | 0.02 | 0.03 | -1.49 | -7.45 | - | - | |
| Net Income | -9.86 | -17.29 | -18.47 | -48.98 | -6.86 | -2.41 | |
| Preferred Dividends & Other Adjustments | - | 0.17 | 0.33 | - | - | - | |
| Net Income to Common | -9.86 | -17.46 | -18.8 | -48.98 | -6.86 | -2.41 | |
| Shares Outstanding (Basic) | 6 | 2 | 1 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 6 | 2 | 1 | 0 | 0 | 0 | |
| Shares Change (YoY) | 167.86% | 49.31% | 206.13% | 310.48% | 8.82% | -6.45% | |
| EPS (Basic) | -1.74 | -8.09 | -13.00 | -103.69 | -59.66 | -22.80 | |
| EPS (Diluted) | -1.75 | -8.09 | -13.00 | -103.69 | -59.66 | -22.80 | |
| Free Cash Flow | -8.17 | -14.1 | -17.73 | -11.65 | -3.89 | -0.65 | |
| Free Cash Flow Per Share | -1.45 | -6.53 | -12.26 | -24.66 | -33.79 | -6.13 | |
| EBITDA | -8.5 | -16.1 | -19.63 | -24.64 | -5.5 | - | |
| D&A For EBITDA | 0.34 | 0.34 | 0.33 | 0.66 | 0.12 | - | |
| EBIT | -8.84 | -16.45 | -19.96 | -25.29 | -5.62 | -2.3 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.